HUTCHMED (China) Future Growth

Future criteria checks 3/6

HUTCHMED (China) is forecast to grow earnings and revenue by 18.7% and 10.1% per annum respectively. EPS is expected to grow by 19.5% per annum. Return on equity is forecast to be 11% in 3 years.

Key information

18.7%

Earnings growth rate

19.5%

EPS growth rate

Pharmaceuticals earnings growth	14.7%
Revenue growth rate	10.1%
Future return on equity	11.0%
Analyst coverage	Good
Last updated	23 Apr 2024

Recent future growth updates

Recent updates

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

Earnings and Revenue Growth Forecasts

AIM:HCM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,022	85	56	46	14
12/31/2025	836	-6	-25	-19	20
12/31/2024	681	-109	-205	-180	19
12/31/2023	838	101	187	219	N/A
9/30/2023	798	36	95	133	N/A
6/30/2023	757	-29	2	48	N/A
3/31/2023	592	-195	-151	-110	N/A
12/31/2022	426	-361	-305	-269	N/A
9/30/2022	414	-308	-276	-246	N/A
6/30/2022	401	-255	-246	-223	N/A
3/31/2022	376	-235	-245	-227	N/A
12/31/2021	356	-195	-221	-204	N/A
9/30/2021	317	-187	-169	-155	N/A
6/30/2021	279	-178	-118	-105	N/A
3/31/2021	258	-151	-95	-83	N/A
12/31/2020	228	-126	-70	-62	N/A
9/30/2020	221	-117	-72	-63	N/A
6/30/2020	209	-110	-88	-79	N/A
3/31/2020	204	-102	-63	-54	N/A
12/31/2019	205	-106	-89	-81	N/A
9/30/2019	205	-93	-86	-77	N/A
6/30/2019	214	-87	-52	-44	N/A
3/31/2019	214	-83	-37	-31	N/A
12/31/2018	214	-75	-39	-33	N/A
9/30/2018	218	-72	-38	-33	N/A
6/30/2018	217	-61	-51	-47	N/A
3/31/2018	230	-39	-54	-49	N/A
12/31/2017	241	-27	-14	-9	N/A
9/30/2017	240	-7	N/A	-4	N/A
6/30/2017	238	13	N/A	1	N/A
3/31/2017	227	12	N/A	-4	N/A
12/31/2016	216	12	N/A	-10	N/A
9/30/2016	200	38	N/A	2	N/A
6/30/2016	200	-8	N/A	-1	N/A
3/31/2016	189	-22	N/A	-5	N/A
12/31/2015	178	-35	N/A	-9	N/A
9/30/2015	168	-80	N/A	-11	N/A
6/30/2015	139	-66	N/A	-6	N/A
3/31/2015	113	-50	N/A	1	N/A
12/31/2014	87	-35	N/A	8	N/A
9/30/2014	72	-20	N/A	11	N/A
6/30/2014	59	7	N/A	21	N/A
3/31/2014	52	8	N/A	13	N/A
12/31/2013	37	26	N/A	5	N/A
9/30/2013	38	10	N/A	0	N/A
6/30/2013	30	13	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCM's forecast earnings growth (18.7% per year) is above the savings rate (1.6%).

Earnings vs Market: HCM's earnings (18.7% per year) are forecast to grow faster than the UK market (12.2% per year).

High Growth Earnings: HCM's earnings are forecast to grow, but not significantly.

Revenue vs Market: HCM's revenue (10.1% per year) is forecast to grow faster than the UK market (3.4% per year).

High Growth Revenue: HCM's revenue (10.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HCM's Return on Equity is forecast to be low in 3 years time (11%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

HUTCHMED (China) Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Consensus revenue estimates decrease by 18%

Consensus EPS estimates increase from loss to US$0.0102 profit

Consensus EPS estimates increase from loss to US$0.0051 profit

Consensus EPS estimates increase from loss to US$0.0016 profit

Consensus EPS estimates upgraded to US$0.0045 loss

Recent updates

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Consensus EPS estimates upgraded to US$0.25 loss

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

CFO & Executive Director recently sold UK£2.4m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

Less than half of directors are independent

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

Now 21% undervalued after recent price drop

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Now 23% undervalued after recent price drop

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer

First half 2022 earnings released

HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China